Cardiff Oncology (NASDAQ:CRDF - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05, Zacks reports. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%.
Shares of NASDAQ CRDF traded down $0.40 during midday trading on Thursday, hitting $4.06. The company's stock had a trading volume of 1,152,580 shares, compared to its average volume of 1,352,222. The firm has a market capitalization of $207.60 million, a price-to-earnings ratio of -4.32 and a beta of 1.77. The business's fifty day simple moving average is $4.06 and its two-hundred day simple moving average is $3.22. Cardiff Oncology has a 1 year low of $1.74 and a 1 year high of $6.42.
In related news, Director Gary W. Pace bought 350,115 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the acquisition, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.60% of the stock is owned by insiders.
Several analysts recently weighed in on CRDF shares. HC Wainwright dropped their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a "buy" rating for the company in a report on Friday, November 8th. Piper Sandler lifted their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a research note on Friday, December 13th.
Read Our Latest Stock Analysis on CRDF
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.